Alex Sanchez, MD
Geriatric Medicine · Elgin, ILNPI 1811164916
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 168 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 10.2% — the pattern of someone who eats at a lot of different presentations. Among geriatric medicine clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 168 payments — averaging $28.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$483
- Otsuka America Pharmaceutical, Inc.$480
- Lilly USA, LLC$433
- Vanda Pharmaceuticals Inc.$415
- Novo Nordisk$410
- Teva Pharmaceuticals USA, Inc.$258
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,63498%
- Education$972%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,731 in reported general payments places this provider in the 95th percentile of 147 geriatric medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 717 | $243,240 |
| Invega SustennaPaliperidone Palmitate | 36 | $110,184 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 12 | $93,937 |
| XareltoRivaroxaban | 254 | $79,474 |
| JardianceEmpagliflozin | 131 | $66,864 |
| XifaxanRifaximin | 60 | $55,874 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $51,629 |
| TrulicityDulaglutide | 40 | $37,374 |
| OzempicSemaglutide | 31 | $32,616 |
| ZenpepLipase/Protease/Amylase | 29 | $31,037 |
| Breo ElliptaFluticasone/Vilanterol | 66 | $29,286 |
| Atorvastatin Calcium | 2,285 | $27,877 |
| JanuviaSitagliptin Phosphate | 55 | $26,938 |
| VelphoroSucroferric Oxyhydroxide | 15 | $25,568 |
| FarxigaDapagliflozin Propanediol | 36 | $22,386 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $123 | $243,240717 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $14 | $189,658290 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $48 | $92,152199 claims |
| GSKBreo Ellipta, Anoro Ellipta, Incruse Ellipta, Trelegy Ellipta | $19 | $72,152205 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $42 | $55,87460 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $433 | $49,17952 claims |
| Novo NordiskOzempic, Fiasp | $410 | $42,31157 claims |
| AstraZenecaFarxiga | $483 | $22,38636 claims |
| NovartisEntresto | $196 | $20,94359 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $79 | $20,841147 claims |
| Astellas Pharma US IncMyrbetriq | $36 | $13,00649 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 147 geriatric medicine providers in Illinois.
Other geriatric medicine in Elgin
- Michael LimArlington Heights$29K
- Hima AtluriDecatur$21K
- Carlos Mella-PicelChicago$9K
- Rekha SharmaHazel Crest$8K
- Beata StykaPalos Heights$6K
- Azeem AhsanCrest Hill$6K
- Adeela CheemaChicago$5K
- Seong ChinGlenview$4K
- Thomas CozziArlington Heights$3K
- Snigdha KolaChicago$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.